25 PhD Positions in Cell Signaling

The scientific laboratory of excellence “Labex SIGNALIFE” is comprised of 6 leading research institutes from Nice, France with the participation of 49 top-level research teams.  SIGNALIFE is a collaborative research program in Life Sciences at the University of Nice Sophia Antipolis financed by the Excellence Initiative of the French Ministry of Researchere in which there are currently 50 International Labex SIGNALIFE PhD Students in our laboratories from three previous successive recruitments. The research teams are grouped around 5 major topics relating to Cell Signaling in Biology:  (1) Cellular architecture of signaling pathways, (2) plasticity and signaling, (3) stress signaling, (4) signaling in aging and disease progression and (5) new principles in signaling and applications.

Fourth wave successful candidates will enroll in the Graduate School of the University of Nice Sophia Antipolis (Life Sciences and Health Doctoral School). This University is a major interdisciplinary campus with over 25 000 students on the French Riviera in the South of France and has state-of-the-art facilities for biomedical and basic research.

The International SIGNALIFE PhD program at the University of Nice-Sophia Antipolis is currently accepting applications for 25 targeted 3-year PhD positions, which will start in September 2016.

Application Deadline:  April 1, 2016

For more information:  http://signalife.unice.fr/4034.php


1st National Festival and International Congress on Stem Cell and Regenerative Medicine

Tarih:  19-21 Mayıs 2016

Yer:  Tehran / İran

During the International Scientific Congress there will be keynote lectures by selected pioneers of stem cell research, panel discussions, meet the professor podiums, oral/poster presentations and training workshops.  The sessions will focus on the most recent scientific findings in the area of Clinical Trials on Stem Cell Research, Stem Cells and Regenerative Medicine Products, Basic Research and Cellular Reprogramming and Trends in IPS Cell Research and the Ethical Issues in this field.  Festival will include various sections like:  Stem Cell Technology and Tec-Marketing, Ideation and Innovation Club, National Award of Stem Cell and Regenerative Medicine, ect.

Web:  http://www.icsc2016.com/enindex.php

Merkezimize kurulacak olan GENKÖK-Biyobank dış basında ilgi buldu

Turkish university set to launch country’s first biobank



Published November 23, 2015

A university in central Turkey readied the country’s first biobank, a repository for DNA and RNA samples, as well as umbilical cord blood, in an effort for a better fight against diseases.

Biobank, which will be launched in 2016 by Erciyes University, will allow researchers to collect and store at least 3 million samples. Samples will be used in determining the genetic features of both people and the diseases they are subject to, and in return, will help scientists develop tailor-made treatments for patients.Professor Yusuf Özkul, director of the university’s Genome and Stem Cell Center, which will oversee the biobank, said the repository would be the first-of-its-kind in Turkey. He said collected cells and other organic materials will be especially helpful in providing faster results in studies for the treatment of rare diseases and diseases that are difficult to diagnosis and treat. “Personalized medicine will be more common in the future, so we need to define genetic characteristics of the society to that extent. Data from the biobank will help us with this matter. For instance, cancer treatment chemotherapy sessions should be varied in their intensity in line with patients’ needs. Biobank will allow us to determine the correct dosage for each patient,” Özkul said. He added that biobank will also keep umbilical cord blood, which is usually thrown away due to the lack of storage units, but is essential for the treatment of bone marrow cancers.

Biobank also aims to help with the development of new drugs from the pharmaceutical industry, especially in testing the drugs on live cells stored in the repository. Özkul said biobank would be the key to the testing of drugs entering the Turkish market, for example, drugs intended for cancer treatment. “Biobank will let us know whether any new drug is efficient for treating diseases Turkish people suffer from, as a drug effective at treating one country’s population, can be ineffective at treating people in another country,” he said, stressing the genetic differences.